【摘要】 目的:分子肝素在慢性阻塞性肺疾病急性加重期(AECOPD)抗凝治疗中的应用价值。方法:将92例AECOPD患者随机分成对照组和治疗组,每组各46例。治疗组患者在对照组常规治疗基础上予低分子肝素4 000 U皮下注射,每天2次,治疗7 d。观察治疗前后患者肺功能指标FEV1及FEV1/FVC%,血气分析指标Pa O2、Pa CO2,血超敏C-反应蛋白(hs-CRP)和血D-二聚体水平的变化情况。结果:两组FEV1、FEV1/FVC%、Pa O2、Pa CO2、hs-CRP和血D-二聚体水平治疗前后比较,治疗组优于对照组(P<0.05)。结论:低分子肝素治疗AECOPD效果明显。更多还原

【Abstract】 Objective: To investigate the use of low-molecular-weight heparin( LMWH) in the anticoagulant therapy of acute exacerbation of chronic obstructive pulmonary disease( AECOPD). Method: Ninety-two AECOPD patients were randomly divided into the control group and treatment group. The treatment group was given 4000 U of LMWH by subcutaneous injection on the basis of the conventional treatment of the control group,twice a day for a week. The changes of lung function parameters of FEV1 and FEV1 / FVC%,blood-gas analysis parameters of Pa O2 and Pa CO2,blood high-sensitivity C-reactive protein( hs-CRP),and blood D-dimer level in patients were observed before and after the treatment. Result: There were significant differences in FEV1,FEV1 /FVC%,Pa O2,Pa CO2,hs-CRP and blood D-dimer level before and after the treatment between the two groups( P < 0. 05). Also,the above parameters in the treatment group were significantly better than those in the control group( P < 0. 05). Conclusion: The effect of LMWH in the treatment of AECOPD is significant; hs-CRP and blood D-dimer level can be parameters for clinical observation.更多还原